Paratek pharmaceuticals revenue
WebIn 2024, Paratek was awarded a contract from the U.S. Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA), now valued at up to $304 million, to support the development of omadacycline for pulmonary anthrax and the U.S.-based commercial manufacturing of NUZYRA. WebParatek Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on March 16 BOSTON, March 08, 2024 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. …
Paratek pharmaceuticals revenue
Did you know?
Web12 Apr 2024 · Some of the companies listed in the study from the complete survey list are Vanda Pharmaceuticals, Merck & Co., Inc., Pfizer Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Sumitomo ... Web10 Apr 2024 · Paratek Pharmaceuticals, Inc. announced that new data from studies with NUZYRA will be presented at the European Congress of Clinical Microbiology & Infectious Diseases . The hybrid conference... April 11, 2024 ... Paratek Pharmaceuticals Announces Full-Year 2024 Revenue of $160.3 Million: AQ. 03/16: Paratek Pharmaceuticals, Inc. …
Web16 Mar 2024 · Paratek Pharmaceuticals (PRTK) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of $0.01. ... Paratek Pharmaceuticals (PRTK) … WebParatek Pharmaceuticals Announces Full-Year 2024 Revenue of $160.3 Million. March 8, 2024. Paratek Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial …
Web3 Jan 2024 · Our estimate is that Paratek can generate on the order of $400 million in revenue by 2028 for CABP and ABBSSI. A larger market for treatment of the rare disease … Web16 Mar 2024 · Paratek generated total revenue of $160.3 million, primarily as a result of strong growth in NUZYRA® commercial revenue. NUZYRA generated full-year net U.S. …
Web9 Apr 2024 · The company reported $0.87 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.90 by ($0.03). The company had revenue of $10.95 billion during the quarter, compared to...
WebNovartis. Feb 2000 - Feb 20099 years 1 month. Launched and exceeded sales goals for the marketing and sale of Starlix, Diovan, Exforge, and Tekturna to Cardiovascular, … smith innovation apsWeb2 Aug 2024 · Clinical program successfully completed to support regulatory applications and potential approval in the U.S. and EUPre-NDA meetings with FDA conf... rival vacuum sealer bags walmartWeb10 Apr 2024 · In 2024, Paratek was awarded a contract from the U.S. Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA), now valued at up to $304 million, to support the development of omadacycline for pulmonary anthrax and the U.S.-based commercial manufacturing of NUZYRA. rival vacuum sealer troubleshootingWeb2 Jan 2024 · When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see Paratek … rival volleyball club long islandWebParatek’s Profile, Revenue and Employees. Paratek is a biopharmaceutical company that researches, develops, and commercializes antibiotic therapies for the treatment of … rivalvry dramacoolWeb3 Nov 2024 · BOSTON, Nov. 03, 2024 (GLOBE NEWSWIRE) — Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), today reported financial results and provided an update on corporate … smith injury lionsWebParatek Pharmaceuticals' NUZYRA® Receives FDA Fast Track Designation for the Treatment of Pulmonary Nontuberculous Mycobacterial (NTM) … rival views of market society